Antimicrobial peptides in nasal secretion and mucosa with respect to Staphylococcus aureus colonization in chronic rhinosinusitis with nasal polyps

Rhinology

Volumn 49, Issue 5, 2011, Pages 554-561

  Thienhaus, Maike Luisa ^a   Wohlers, Janet ^a   Podschun, Rainer ^b   Hedderich, Jürgen ^b   Ambrosch, Petra ^a   Laudien, Martin ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Antimicrobial peptides; Chronic rhinosinusitis; HBD 3; LL 37; Nasal polyps; Staphylococcus aureus

Indexed keywords

ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; BETA DEFENSIN; BETA DEFENSIN 3, HUMAN; BETA-DEFENSIN 3, HUMAN; CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE;

ADULT; ARTICLE; CHRONIC DISEASE; COMORBIDITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; ISOLATION AND PURIFICATION; MALE; METABOLISM; MICROBIOLOGY; NOSE MUCOSA; NOSE POLYP; PATHOPHYSIOLOGY; RHINITIS; SECRETION; SINUSITIS; STAPHYLOCOCCUS AUREUS;

ADULT; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BETA-DEFENSINS; CATHELICIDINS; CHRONIC DISEASE; COMORBIDITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NASAL MUCOSA; NASAL POLYPS; RHINITIS; SINUSITIS; STAPHYLOCOCCUS AUREUS;

EID: 84856621428     PISSN: 03000729     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Fokkens W, Lund V, Mullol J. European position paper on rhi-nosinusitis and nasal polyps. Rhinol Suppl 2007; 20: 1-136.
2. Vento SI, Ertama LO, Hytonen ML, Wolff CH, Malmberg CH. Nasal polyposis: clinical course during 20 years. Ann Allergy Asthma Immunol. 2000; 85: 209-214.
3. Bachert C, Gevaert P, Holtappels G, Johansson SG, van Cauwenberge P. Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J Allergy Clin Immunol. 2001; 107: 607-614.
4. Slavin RG. Nasal polyps and sinusitis. JAMA. 1997; 278: 1849-1854.
5. Bhattacharyya N. The role of infection in chronic rhinosinusitis. Curr Allergy Asthma Rep. 2002; 2: 500-506.
6. Zacharek MA, Krouse JH. The role of allergy in chronic rhinosi-nusitis. Curr Opin Otolaryngol Head Neck Surg. 2003; 11: 196-200.
7. Dykewicz MS. 7. Rhinitis and sinusitis. J Allergy Clin Immunol. 2003; 111 (2 Suppl): S520-S529.
8. Gevaert P, Holtappels G, Johansson SG, Cuvelier C, Cauwenberge P, Bachert C. Organization of secondary lymphoid tissue and local IgE formation to Staphylococcus aureus enterotoxins in nasal polyp tissue. Allergy. 2005; 60: 71-79.
9. Laudien M, Gadola SD, Podschun R, Hedderich J, Paulsen J, Reinhold-Keller E et al. Nasal carriage of Staphylococcus aureus and endonasal activity in Wegener s granulomatosis as compared to rheumatoid arthritis and chronic Rhinosinusitis with nasal polyps. Clin Exp Rheumatol. 2010; 28 (1 Suppl 57): 51-55.
10. Seiberling KA, Conley DB, Tripathi A, Grammer LC, Shuh L, Haines GK, et al. Superantigens and chronic rhinosi-nusitis: detection of staphylococcal exotoxins in nasal polyps. Laryngoscope. 2005; 115: 1580-1585.
11. Wang M, Shi P, Chen B, Zhang H, Jian J, Chen X et al. The role of superantigens in chronic rhinosinusitis with nasal polyps. ORL J Otorhinolaryngol Relat Spec. 2008; 70: 97-103.
12. Van Zele T, Gevaert P, Watelet JB, Claeys G, Holtappels G, Claeys C et al. Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis. J Allergy Clin Immunol. 2004; 114: 981-983.
13. Patou J, Gevaert P, Van Zele T, Holtappels G, van Cauwenberge P, Bachert C. Staphylococcus aureus enterotoxin B, protein A, and lipoteichoic acid stimulations in nasal polyps. J Allergy Clin Immunol. 2008; 121: 110-115.
14. Clement S, Vaudaux P, Francois P, Schrenzel J, Huggler E, Kampf S et al. Evidence of an intracellular reservoir in the nasal mucosa of patients with recurrent Staphylococcus aureus rhinosi-nusitis. J Infect Dis. 2005; 192: 1023-1028.
15. Bals R. Epithelial antimicrobial peptides in host defense against infection. Respir Res. 2000; 1: 141-150.
16. Kern RC, Conley DB, Walsh W, Chandra R, Kato A, Tripathi-Peters A et al. Perspectives on the etiology of chronic rhinosinusitis: an immune barrier hypothesis. Am J Rhinol. 2008; 22: 549-559.
17. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol. 2003; 3: 710-20.
18. De Smet K, Contreras R. Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol Lett. 2005; 27: 1337-1347.
19. Garcia JR, Jaumann F, Schulz S, Krause A, Rodriguez-Jimenez J, Forssmann U et al. Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell Tissue Res. 2001; 306: 257-264.
20. Harder J, Bartels J, Christophers E, Schroder JM. Isolation and characterization of human beta -defensin-3, a novel human induc-ible peptide antibiotic. J Biol Chem. 2001; 276: 5707-5713.
21. Bals R, Wang X, Zasloff M, Wilson JM. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci U S A. 1998; 95: 9541-9546.
22. Nijnik A, Hancock RE. The roles of cathelicidin LL-37 in immune defences and novel clinical applications. Curr Opin Hematol. 2009; 16: 41-47.
23. Hata TR, Gallo RL. Antimicrobial peptides, skin infections, and atopic dermatitis. Semin Cutan Med Surg. 2008; 27: 144-150.
24. Duits LA, Rademaker M, Ravensbergen B, van Sterkenburg MA, van Strijen E, Hiemstra PS et al. Inhibition of hBD-3, but not hBD-1 and hBD-2, mRNA expression by corticosteroids. Biochem Biophys Res Commun. 2001; 280: 522-525.
25. Kim ST, Cha HE, Kim DY, Han GC, Chung YS, Lee YJ et al. Antimicrobial peptide LL-37 is upregulated in chronic nasal inflammatory disease. Acta Otolaryngol. 2003; 123: 81-85.
26. Nell MJ, Tjabringa GS, Vonk MJ, Hiemstra PS, Grote JJ. Bacterial products increase expression of the human cathelicidin hCAP-18/LL-37 in cultured human sinus epithelial cells. FEMS Immunol Med Microbiol. 2004; 42: 225-231.
27. Ooi EH, Wormald PJ, Carney AS, James CL, Tan LW. Human cathelicidin antimicrobial peptide is up-regulated in the eosi-nophilic mucus subgroup of chronic rhinosinusitis patients. Am J Rhinol. 2007; 21: 395-401.
28. Ooi EH, Wormald PJ, Carney AS, James CL, Tan LW. Fungal allergens induce cathelicidin LL-37 expression in chronic rhinosi-nusitis patients in a nasal explant model. Am J Rhinol. 2007; 21: 367-372.
29. Chen PH, Fang SY. The expression of human antimicrobial pep-tide LL-37 in the human nasal mucosa. Am J Rhinol. 2004; 18: 381-385.
30. Laudien M, Dressel S, Harder J, Glaser R. Differential expression pattern of antimicrobial peptides in nasal mucosa and secretion. Rhinology. 2011; 49: 107-111.
31. Holtfreter S, Grumann D, Schmudde M, Nguyen HT, Eichler P, Strommenger B et al. Clonal distribution of superantigen genes in clinical Staphylococcus aureus isolates. J Clin Microbiol. 2007; 45: 2669-2680.
32. Ball SL, Siou GP, Wilson JA, Howard A, Hirst BH, Hall J. Expression and immunolocalisation of antimicrobial peptides within human palatine tonsils. J Laryngol Otol. 2007; 121: 973-978.
33. Harder J, Meyer-Hoffert U, Wehkamp K, Schwichtenberg L, Schroder JM. Differential gene induction of human beta-defensins (hBD-1, -2, -3, and -4) in keratinocytes is inhibited by retinoic acid. J Invest Dermatol. 2004; 123: 522-529.
34. Hui Y, Wohlers J, Podschun R, Hedderich J, Lamprecht P, Ambrosch P et al. Antimicrobial peptides in nasal secretion and mucosa with respect to S. aureus colonization in Wegener s granu-lomatosis. Clin Exp Rheumatol. 2011; 29 (1 Suppl 64): S49-56.
35. Quinn GA, Cole AM. Suppression of innate immunity by a nasal carriage strain of Staphylococcus aureus increases its colonization on nasal epithelium. Immunology. 2007; 122: 80-89.
36. Lysenko ES, Gould J, Bals R, Wilson JM, Weiser JN. Bacterial phosphorylcholine decreases susceptibility to the antimicrobial peptide LL-37/hCAP18 expressed in the upper respiratory tract. Infect Immun. 2000; 68: 1664-1671.
37. Tjabringa GS, Vos JB, Olthuis D, Ninaber DK, Rabe KF, Schalkwijk J et al. Host defense effector molecules in mucosal secretions. FEMS Immunol Med Microbiol. 2005; 45: 151-158.
38. Sachse F, Becker K, von EC, Metze D, Rudack C. Staphylococcus aureus invades the epithelium in nasal polyposis and induces IL-6 in nasal epithelial cells in vitro. Allergy. 2010; 65: 1430-1437.
39. Laube DM, Yim S, Ryan LK, Kisich KO, Diamond G. Antimicrobial peptides in the airway. Curr Top Microbiol Immunol. 2006; 306: 153-182.
40. Wehkamp J, Harder J, Weichenthal M, Mueller O, Herrlinger KR, Fellermann K et al. Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2003; 9: 215-223.
41. Schreiber S, Rosenstiel P, Albrecht M, Hampe J, Krawczak M. Genetics of Crohn disease, an archetypal inflammatory barrier disease. Nat Rev Genet. 2005; 6: 376-388.
42. Sahly H, Schubert S, Harder J, Rautenberg P, Ullmann U, Schroder J et al. Burkholderia is highly resistant to human Beta-defensin 3. Antimicrob Agents Chemother. 2003; 47: 1739-1741.
43. Glaser R, Meyer-Hoffert U, Harder J, Cordes J, Wittersheim M, Kobliakova J et al. The antimicrobial protein psoriasin (S100A7) is upregulated in atopic dermatitis and after experimental skin barrier disruption. J Invest Dermatol. 2009; 129: 641-649.
44. Chen X, Niyonsaba F, Ushio H, Okuda D, Nagaoka I, Ikeda S et al. Synergistic effect of antibacterial agents human beta-defensins, cathelicidin LL-37 and lysozyme against Staphylococcus aureus and Escherichia coli. J Dermatol Sci. 2005; 40: 123-132.
45. Claeys S, de Belder T, Holtappels G, Gevaert P, Verhasselt B, van Cauwenberge P et al. Human beta-defensins and toll-like receptors in the upper airway. Allergy. 2003; 58: 748-753.
46. Iwase T, Uehara Y, Shinji H, Tajima A, Seo H, Takada K et al. Staphylococcus epidermidis Esp inhibits Staphylococcus aureus biofilm formation and nasal colonization. Nature. 2010; 465: 346-349.
47. Gluck U, Gebbers JO. Ingested probiotics reduce nasal col onization with pathogenic bacteria (Staphylococcus aureus, Streptococcus pneumoniae, and beta-hemolytic streptococci). Am J Clin Nutr. 2003; 77: 517-520.